Pear Therapeutics is seeking marketing authorization from the Food and Drug Administration (FDA) for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.
In patients with Parkinson disease who receive subthalamic nucleus deep brain stimulation, suicide behaviors tend to occur during the first 3 years after the procedure.
The benefit of CPAP was seen for depression but not anxiety symptoms in patients with obstructive sleep apnea.
Screening for and treating depression in patients with diabetes may be associated with a lower mortality risk.
Every 10-ng/mL increase in serum 25-hydroxyvitamin D was associated with a 12% decrease in the risk for depression in older adults.
Ketamine is gaining ground as a promising option for treatment-resistant depression, but not every clinician is buying in. We review clinical evidence and concerns surrounding the drug.
Researchers completed a comprehensive meta-analysis examining existing literature to study the relationship between alopecia areata, anxiety, and depression.
Benzodiazepine monotherapy continues to be used to treat depression despite American Psychiatric Association guidelines, and even in cases of concomitant opioid use.
Patients with asthma have demonstrated an elevated risk for depression and anxiety that is potentially twice as high as that in the general population.
Participants of a cognitive behavioral health-based online intervention showed reduced symptoms of anxiety and depression and high levels of satisfaction in both a routine healthcare setting and a controlled research study.
